GLAUCOMA RESEARCH HIGHLIGHTS

The latest findings from the 2018 meeting of the American Glaucoma Society in New York City.

BY GEOFFREY T. EMERICK, MD

B

ringing together more than 1,500 registrants, the 28th Annual Meeting of the American Glaucoma Society (AGS) was the largest in the organization’s history. Held in March 2018, the conference featured reports on important findings from clinical trials and scientific research, a day devoted to glaucoma surgery, five symposia, 25 paper presentations, 146 posters, 11 breakfast roundtable discussions, and two workshops. Of note, Joel S. Schuman, MD, delivered the AGS Lecture “Glaucoma—From the Artisanal to the Defined,” in which he provided a fascinating overview of the history of ophthalmology from a glaucomatologist’s perspective. In the Clinician Scientist Lecture, “Glaucoma at the Center of the Earth,” Donald L. Budenz, MD, MPH, discussed his population studies in Ghana, a country with one of the highest rates of glaucoma in the world.

Prominent topics at this year’s AGS meeting included microinvasive glaucoma surgery (MIGS), new developments in visual function testing, and the practical application of clinical trial results. For this article, I selected studies I believe have the potential to change glaucoma management today or in the near future.

MIGS DEVICES

The Hydrus Microstent (Ivantis; investigational use only; Figure 1) is a metallic intracanalicular scaffold that provides 90° of outflow effect. Thomas W. Samuelson, MD, presented 2-year data from the device’s FDA trial, in which 556 patients were randomly assigned to cataract surgery alone or with implantation of the Hydrus. Preoperative mean IOP was approximately 25 mm Hg in both groups. At 24 months, mean reduction in diurnal IOP was -7.5 mm Hg in the Hydrus group and -5.2 mm Hg in the control group. Seventy-seven percent of Hydrus patients achieved the primary study endpoint of a 20% or greater reduction in IOP compared with 58% of controls. At 2 years, 78% of Hydrus patients versus 48% of controls remained medication-free. Complications associated with the stent included transient hyphema in 1.1% of patients and obstruction of the device by peripheral anterior synechiae in 3.8% of patients. No cases of hypotony occurred. In the control group, 2.7% of patients experienced a significant IOP spike and 2.1% required glaucoma surgery.

Douglas J. Rhee, MD, presented the 12-month findings of a trial comparing the Hydrus Microstent with two current-generation iStent Trabecular MicroBypass Stents (model GTS100, Glaukos) as a standalone procedure. Investigators randomly assigned 152 patients without a history of incisional glaucoma surgery to receive the Hydrus or two iStents; approximately two-thirds of the patients were phakic. Mean unmedicated IOP was about 27 mm Hg on an average of 2.5 medications.

At 12 months, mean IOP was approximately 18 mm Hg in both groups. Patients in the Hydrus group required significantly fewer medications than those in the iStent group (mean, 1 vs 1.5). The Hydrus patients were also more likely than the iStent patients to be free of medication use (47% vs 24%). Few complications were observed. Device obstruction/adhesions occurred in 5% of the Hydrus group and 13% of the iStent group. One patient in each group required trabeculectomy.

ARTIFICIAL INTELLIGENCE

Artificial intelligence (AI) is the general concept of machines acting in a “smart” way. One application of AI is machine learning, which refers to a computer’s ability to learn without being explicitly programmed to do so. Deep learning systems are many-layered neural networks that can recognize patterns, a capability that is improved by using very large data sets. AI has received a great deal of attention in ophthalmology since the December publication of an article describing the use of a deep learning system to detect diabetic retinopathy in retinal images.

Machine learning could also be used to recognize abnormal optic discs or to detect glaucomatous progression. At the AGS meeting, Osamah Saeedi, MD, reported on a project using 90,713 visual fields of 13,156 eyes...
AT A GLANCE

- The Hydrus Microstent, an investigational intracanalicular scaffold providing 90° of outflow effect, reduced IOP and the need for medication in two studies.
- In the future, machine learning may aid clinicians in detecting glaucomatous progression.
- Short-term treatment with topical antiinflammatory drugs after selective laser trabeculoplasty may improve the procedure’s efficacy.
- Primary open-angle glaucoma is associated with impaired blood flow, as measured in nailfold capillaries.

from the Glaucoma Research Network collection. Investigators used available progression algorithms, including the Visual Field Index, to classify the fields as progressing or stable. The fields were used to train six different machine learning systems. Glaucoma specialists graded a subset of eyes for comparison. The Visual Field Index had an accuracy (ability to differentiate progression from stability) of 95%. The machine learning classifiers had an accuracy ranging from 83% to 88%, a sensitivity of 76% to 85%, and a specificity of 89% to 94%. The investigators concluded that, in the future, machine learning could help clinicians determine which patients are experiencing disease progression. (For more coverage of AI in glaucoma care, see January/February 2018 and July/August 2018 issues of Ophthalmology.)

Laser Trabeculoplasty

Should patients instill topical steroids or nonsteroidal antiinflammatory drugs (NSAIDs) after undergoing selective laser trabeculoplasty (SLT)? A 2014 study of 125 eyes with baseline IOPs around 19 mm Hg found no difference in outcomes, but many clinicians continue to prescribe NSAID drops routinely after SLT. To study the matter further, investigators conducted a randomized multicenter trial that involved 96 eyes of 85 patients with an IOP higher than 18 mm Hg. Sylvia Groth, MD, of Stanford University presented the results at the AGS meeting.

Patients received either prednisolone acetate 1%, ketorolac 0.5%, or artificial tears dosed four times a day for 4 days after SLT. Most patients had primary open-angle glaucoma (POAG), and baseline IOP was approximately 23 mm Hg in all three groups. At 6 weeks, there was no significant difference in IOP among the groups, but patients in both the NSAID and steroid groups showed a greater mean decrease in IOP at week 12 compared with the placebo group: -6.2, -5.2, and -3.0 mm Hg, respectively. The investigators concluded that the effect of SLT may depend on the activation of inflammatory signaling pathways and that modulating the impact through the short-term use of NSAID or steroid drops may improve results.

Systemic Factors

Blood flow dysregulation has been described extensively in patients with glaucoma. One way to directly assess the systemic vasculature is through video measurement of blood flow in the nailfold. Jonathan Chou, MD, presented the results of a study evaluating this technique in 67 POAG patients and 63 control patients (Figure 2). Mean blood velocity was 328.3 µm/s in POAG patients and 573.9 µm/s in controls. In a multivariate analysis that controlled for multiple factors (eg, age, blood pressure, smoking, diabetes), every µm/s increase in blood velocity was associated with a 0.55% reduced risk of POAG. Mean blood flow was much lower in POAG patients than in controls (27 vs 50 pl/s). Every pl/s increase in blood flow was associated with a 6% decreased risk of POAG. This association was strong in both high-tension and normal-tension glaucoma. The investigators postulated that a better understanding of decreased peripheral capillary perfusion in POAG could improve diagnosis and treatment.


GEOFFREY T. EMERICK, MD

- Associate Clinical Professor of Ophthalmology, University of Connecticut School of Medicine, Farmington, Connecticut
- gtemerick@gmail.com
- Financial disclosure: None